Eli Lilly and Company $LLY Stake Raised by D.A. Davidson & CO.

D.A. Davidson & CO. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 5.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,111 shares of the company’s stock after acquiring an additional 2,211 shares during the period. D.A. Davidson & CO.’s holdings in Eli Lilly and Company were worth $35,945,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department raised its stake in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Blume Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares in the last quarter. Finally, IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $35,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY opened at $799.85 on Wednesday. The firm has a market capitalization of $757.03 billion, a P/E ratio of 52.28, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. The stock’s 50 day moving average price is $759.77 and its two-hundred day moving average price is $766.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of recent research reports. Morgan Stanley cut their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. Berenberg Bank reissued a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. UBS Group cut their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Jamere Jackson acquired 200 shares of the stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock valued at $2,894,841 in the last quarter. 0.14% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.